DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,077,441 | +4.3% | 56,741 | +0.9% | 3.88% | +8.9% |
| Q2 2023 | $13,500,480 | -4.7% | 56,252 | +0.0% | 3.56% | -10.5% |
| Q1 2023 | $14,171,201 | -4.8% | 56,226 | +0.3% | 3.98% | -9.9% |
| Q4 2022 | $14,886,081 | -0.3% | 56,085 | -3.0% | 4.42% | -5.3% |
| Q3 2022 | $14,928,000 | +1.8% | 57,794 | -0.1% | 4.66% | +4.9% |
| Q2 2022 | $14,667,000 | -13.8% | 57,848 | -0.2% | 4.45% | +2.4% |
| Q1 2022 | $17,006,000 | -10.6% | 57,975 | +0.3% | 4.34% | -5.0% |
| Q4 2021 | $19,012,000 | +4.3% | 57,787 | -3.5% | 4.57% | -6.1% |
| Q3 2021 | $18,236,000 | +9.9% | 59,904 | -3.1% | 4.87% | +10.4% |
| Q2 2021 | $16,594,000 | +16.5% | 61,831 | -2.3% | 4.41% | +7.6% |
| Q1 2021 | $14,239,000 | +0.5% | 63,266 | -0.8% | 4.10% | -2.6% |
| Q4 2020 | $14,174,000 | +1.1% | 63,800 | -2.0% | 4.21% | -5.7% |
| Q3 2020 | $14,023,000 | +19.3% | 65,131 | -2.0% | 4.46% | +14.0% |
| Q2 2020 | $11,758,000 | +26.3% | 66,485 | -1.2% | 3.92% | +6.3% |
| Q1 2020 | $9,308,000 | -10.2% | 67,268 | -0.4% | 3.68% | +9.7% |
| Q4 2019 | $10,363,000 | +5.6% | 67,531 | -0.6% | 3.36% | -0.6% |
| Q3 2019 | $9,814,000 | -0.2% | 67,950 | -1.3% | 3.38% | -1.9% |
| Q2 2019 | $9,835,000 | +7.9% | 68,812 | -0.3% | 3.44% | +5.7% |
| Q1 2019 | $9,112,000 | +27.4% | 69,023 | -0.5% | 3.26% | +8.1% |
| Q4 2018 | $7,155,000 | -5.0% | 69,373 | +0.1% | 3.01% | +17.8% |
| Q3 2018 | $7,533,000 | +10.1% | 69,333 | +0.0% | 2.56% | +2.2% |
| Q2 2018 | $6,842,000 | +1.1% | 69,331 | +0.3% | 2.50% | -1.5% |
| Q1 2018 | $6,768,000 | +5.8% | 69,126 | +0.3% | 2.54% | +8.7% |
| Q4 2017 | $6,398,000 | +20.7% | 68,926 | +11.5% | 2.34% | +22.1% |
| Q3 2017 | $5,301,000 | +10.5% | 61,810 | +8.8% | 1.91% | +7.8% |
| Q2 2017 | $4,796,000 | +7.8% | 56,815 | +9.2% | 1.77% | -2.2% |
| Q1 2017 | $4,448,000 | +37.4% | 52,018 | +25.1% | 1.81% | +29.3% |
| Q4 2016 | $3,238,000 | +34.8% | 41,586 | +35.8% | 1.40% | +37.0% |
| Q3 2016 | $2,402,000 | -7.3% | 30,626 | +19.4% | 1.02% | -6.1% |
| Q2 2016 | $2,590,000 | +80.1% | 25,656 | +69.3% | 1.09% | +75.0% |
| Q1 2016 | $1,438,000 | – | 15,155 | – | 0.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |